Natera, Inc. (NTRA)

NMS – Real Time Price. Currency in USD

261.91

+1.17 (0.45%)

At close: Jun 26, 2026, 4:00 PM EDT

261.32

-0.59 (-0.22%)

After-hours: Jun 26, 2026, 7:51 PM EDT

13.06.2026

Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

08.06.2026

NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC

Natera teams with CytoDyn to track ctDNA in CLOVER Phase 2, using Signatera to map leronlimab response in metastatic colorectal cancer.

04.06.2026

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

AUSTIN, Texas & VANCOUVER, Wash.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insi.

03.06.2026

Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)

Most investors' portfolios hold at least a couple of the market's biggest companies, just because these names are best-known to most investors. These crowded trades in already-massive companies, however, can mean their potential upside is limited.

03.06.2026

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company's board of directors. “Tom and Eric have helped lead some of the most important advances in modern oncology, and we are thrilled to welcome them to the Board,” said Matthew Rabinowitz, Ph.D., co-founder of Natera and executive chairman of the board. “Their deep expertise across evidence.

$NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial$

01.06.2026

NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial

Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge response.

29.05.2026

Why Natera Is My Favorite Stock Idea for the Rest of 2026

It's hard to pick just one favorite stock idea for the rest of the year. It's been a blistering-hot 2026, as the AI revolution keeps rolling ahead.

Videos

10.05.2026

Positive

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Press releases

04.06.2026

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

03.06.2026

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

$Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma$

29.05.2026

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration, Signatera will be used to longitudinally assess molecular response in patients with refractory melanoma enrolled in Diakonos' DOC-RM Phase I/II investigational immunotherapy.

28.05.2026

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionAL (SIGNAL)-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early-stage breast cancer. The current standard of care recommends two or three years of an adjuvant CDK4/6 inhibitor in combination with endocrine therapy for patients with intermediat.

Natera, Inc. (NTRA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Natera, Inc. (NTRA)

Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial

Why Natera Is My Favorite Stock Idea for the Rest of 2026

Videos

Press releases

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial

Why Natera Is My Favorite Stock Idea for the Rest of 2026

Videos

Press releases

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

Search stocks

Natera, Inc. (NTRA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Natera, Inc. (NTRA)

Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial

Why Natera Is My Favorite Stock Idea for the Rest of 2026

Videos

Press releases

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial

Why Natera Is My Favorite Stock Idea for the Rest of 2026

Videos

Press releases

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer